IDEAYA Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 18, 2025
IDYA$31.75-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)
The following documents are filed as part of this report:
(1)
FINANCIAL STATEMENTS
The following documents are included on pages F-1 through F-31 attached hereto and are filed as part of this Annual Report on Form 10-K.
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Audited Financial Statements: | |
| Balance Sheets | F-4 |
| Statements of Operations and Comprehensive Loss | F-5 |
| Statements of Stockholders’ Equity | F-6 |
| Statements of Cash Flows | F-7 |
| Notes to Financial Statements | F-8 |
(2)
FINANCIAL STATEMENT SCHEDULES
All schedules to the financial statements are omitted as the required information is either inapplicable or presented in the financial statements.
(3)
EXHIBITS
The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this report.
Exhibit Index
(a) Exhibits.
| ExhibitNumber · Exhibit Description · Incorporated by Reference · FiledHerewith | |||||
|---|---|---|---|---|---|
| Form · Date · Number | |||||
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 5/28/2019 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 8-K | 5/28/2019 | 3.2 | |
| 4.1 | Reference is made to Exhibits 3.1 through 3.2. | ||||
| 4.2 | Form of Common Stock Certificate. | S-1/A | 5/13/2019 | 4.2 | |
| 4.3 | Description of Common Stock. | X | |||
| 4.4 | Form of April 2023 Pre-funded Warrant. | 8-K | 4/27/2023 | 4.1 | |
| 4.5 | Form of October 2023 Pre-funded Warrant. | 8-K | 10/27/2023 | 4.1 | |
| 4.6 | Form of July 2024 Pre-funded Warrant. | 8-K | 7/11/2024 | 4.1 | |
| 10.1† | License Agreement by and between IDEAYA Biosciences, Inc. and Novartis International Pharmaceutical, Inc. dated as of September 19, 2018. | S-1 | 4/26/2019 | 10.1 | |
| 10.2(a)† | Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of April 28, 2017. | S-1 | 4/26/2019 | 10.2(a) | |
| 10.2(b) | Amendment #1 to Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of April 24, 2019. | S-1 | 4/26/2019 | 10.2(b) | |
| 10.2(c) | Amendment #2 to Evaluation, Option and License Agreement by and among IDEAYA Biosciences, Inc., Cancer Research Technology Ltd. and University of Manchester dated as of March 3, 2020. | 10-K | 3/24/2020 | 10.2(c) | |
| 10.3(a)# | 2019 Incentive Award Plan. | S-1/A | 5/13/2019 | 10.5(a) | |
| 10.3(b)# | Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan. | S-1/A | 5/13/2019 | 10.5(b) | |
| 10.3(c)# | Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2019 Incentive Award Plan. | S-1/A | 5/13/2019 | 10.5(c) | |
| 10.3(d)# | Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Incentive Award Plan. | S-1/A | 5/13/2019 | 10.5(d) | |
| 10.4# | Employee Stock Purchase Plan. | S-1/A | 5/13/2019 | 10.6 | |
| 10.5(a)# | 2015 Equity Incentive Plan, as amended. | S-1 | 4/26/2019 | 10.4(a) | |
| 10.5(b)# | Form of Stock Option Agreement under the 2015 Equity Incentive Plan. | S-1 | 4/26/2019 | 10.4(b) | |
| 10.5(c)# | Form of Early Exercise Stock Option Agreement under the 2015 Equity Incentive Plan. | S-1 | 4/26/2019 | 10.4(c) | |
| 10.5(d)# | Form of Stock Purchase Right Grant Notice and Restricted Stock Purchase Agreement under 2015 Equity Incentive Plan. | S-1 | 4/26/2019 | 10.4(d) | |
| 10.6(a)# | 2023 Employment Inducement Award Plan. | S-8 | 3/7/2023 | 99.3(a) | |
| 10.6(b)# | Amendment to the 2023 Employment Inducement Award Plan. | S-8 | 8/6/2024 | 99.1(c) | |
| 10.6(c)# | Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Employment Inducement Award Plan. | S-8 | 3/7/2023 | 99.3(b) | |
| 10.7# | Employment Agreement by and between IDEAYA Biosciences, Inc. and Yujiro Hata. | S-1/A | 5/13/2019 | 10.7(b) | |
| 10.8# | Amended and Restated Employment Agreement by and between IDEAYA Biosciences, Inc. and Michael White. | 10-Q | 11/15/2021 | 10.2 | |
| 10.9# | Employment Agreement by and between IDEAYA Biosciences, Inc. and Darrin Beaupre. | 10-K | 3/7/2023 | 10.10 | |
| 10.10# | Amended and Restated Employment Agreement, dated as of July 1, 2023 by and between IDEAYA Biosciences, Inc. and Andres Ruiz Briseno. | 10-Q | 8/10/2023 | 10.5 | |
| 10.11#† | Employment Agreement by and between IDEAYA Biosciences, Inc. and Douglas Snyder. | 10-Q | 11/4/2024 | 10.2 | |
| 10.12#† | Employment Agreement by and between IDEAYA Biosciences, Inc. and Stu Dorman. | X | |||
| 10.13# | Non-Employee Director Compensation Program. | 10-K | 2/20/2024 | 10.13 | |
| 10.14 | Form of Indemnification Agreement for Directors and Officers. | S-1/A | 5/13/2019 | 10.14 | |
| 10.15 | Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of August 26, 2016. | S-1 | 4/26/2019 | 10.15 | |
| 10.16 | Letter Agreement Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of January 27, 2017. | S-1 | 4/26/2019 | 10.16 | |
| 10.17 | First Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of May 31, 2018. | S-1 | 4/26/2019 | 10.17 | |
| 10.18 | Second Amendment to Lease Agreement by and between IDEAYA Biosciences, Inc. and ARE-SAN FRANCISCO NO. 17, LLC dated as of September 30, 2019. | 10-Q | 11/13/2019 | 10.11 | |
| 10.19(a)† | Option and License Agreement by and between IDEAYA Biosciences, Inc. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., dated as of July 30, 2024. | 10-Q | 11/4/2024 | 10.1 | |
| 10.19(b)† | First Amendment to Option and License Agreement by and between IDEAYA Biosciences, Inc. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., dated as of December 12, 2024. | X | |||
| 10.20(a)† | Clinical Trial Collaboration and Supply Agreement by and between IDEAYA Biosciences, Inc. and Pfizer Inc. dated as of March 11, 2020. | 10-Q | 5/12/2020 | 10.4 | |
| 10.20(b)† | Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of September 23, 2020. | 10-Q | 11/12/2020 | 10.1 | |
| 10.20(c)† | Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of April 8, 2021. | 10-Q | 5/10/2021 | 10.1 | |
| 10.20(d)† | Amendment No. 3 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of August 9, 2021. | 10-Q | 11/15/2021 | 10.1 | |
| 10.20(e)† | Amendment No. 4 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of May 12, 2023. | 10-Q | 8/10/2023 | 10.1 | |
| 10.20(f)† | Amendment No. 5 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of December 16, 2024 | X | |||
| 10.21(a)† | Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of June 15, 2020. | 10-Q | 8/12/2020 | 10.3 | |
| 10.21(b) | Amendment No. 1 to Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of October 23, 2020. | 10-K | 3/18/2022 | 10.18 | |
| 10.21(c)† | Amendment No. 2. to Collaboration, Option and License Agreement by and between GlaxoSmithKline Intellectual Property (No. 4) Limited and IDEAYA Biosciences, Inc. dated as of January 31, 2022. | 10-Q | 5/10/2022 | 10.3 | |
| 10.22(a)† | Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of March 9, 2022. | 10-Q | 5/10/2022 | 10.1 | |
| 10.22(b)† | Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement by and between Pfizer Inc. and IDEAYA Biosciences, Inc. dated as of May 10, 2023 | 10-Q | 8/10/2023 | 10.2 | |
| 10.23† | Clinical Trial Collaboration and Supply Agreement by and between Amgen Inc. and IDEAYA Biosciences, Inc. dated as of July 26, 2022. | 10-Q | 11/8/2022 | 10.1 | |
| 10.24† | Clinical Study Collaboration and Supply Agreement by and between Gilead Sciences, Inc. and IDEAYA Biosciences, Inc. dated as of November 29, 2023 | 10-K | 2/20/2024 | 10.23 | |
| 10.25(a) | Lease Agreement by and between DW LSP 5000 Shoreline, LLC and IDEAYA Biosciences, Inc. dated as of June 1, 2023. | 10-Q | 8/10/2023 | 10.3 | |
| 10.25(b)† | First Amendment to Lease Agreement by and between DW LSP 5000 Shoreline, LLC and IDEAYA Biosciences, Inc. dated as of May 10, 2024. | X | |||
| 10.26 | Office Lease Agreement by and between AAT TORREY 13-14, LLC and IDEAYA Biosciences, Inc. dated as of November 14, 2023 | 10-K | 2/20/2024 | 10.25 | |
| 10.27† | Option and License Agreement by and between IDEAYA Biosciences, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd., dated as of December 27, 2024. | X | |||
| 10.28† | Clinical Trial Collaboration and Supply Agreement by and between IDEAYA Biosciences, Inc. and MSD International Business GmbH, dated as of March 8, 2024 | 10-Q | 5/7/2024 | 10.1 | |
| 10.29 | Open Market Sales Agreement by and between IDEAYA Biosciences, Inc. and Jefferies LLC, dated as of January 19, 2024. | 8-K | 1/19/2024 | 10.1 | |
| 19.1† | Insider Trading Compliance Policy. | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | |||
| 24.1 | Power of Attorney (included on signature page to this Annual Report on Form 10-K). | X | |||
| 31.1 | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 97 | Policy for Recovery of Erroneously Awarded Compensation. | 10-K | 2/20/2024 | 97 | |
| 101.INS | Inline XBRL Instance Document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents | X | |||
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) | X | |||
† Portions of this exhibit have been omitted pursuant to Regulation S-K, Item 601(b)(10) or certain schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.